The latest price target for Atara Biotherapeutics (NASDAQ:ATRA) was reported by Canaccord Genuity on January 17, 2025. The analyst firm set a price target for $17.00 expecting ATRA to rise to within 12 months (a possible 180.53% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Atara Biotherapeutics (NASDAQ:ATRA) was provided by Canaccord Genuity, and Atara Biotherapeutics maintained their buy rating.

The last upgrade for Atara Biotherapeutics Inc happened on August 16, 2024 when Mizuho raised their price target to $18. Mizuho previously had a neutral for Atara Biotherapeutics Inc.

The last downgrade for Atara Biotherapeutics Inc happened on November 9, 2023 when Evercore ISI Group changed their price target from N/A to N/A for Atara Biotherapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on January 17, 2025 so you should expect the next rating to be made available sometime around January 17, 2026.

While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a maintained with a price target of $21.00 to $17.00. The current price Atara Biotherapeutics (ATRA) is trading at is $6.06, which is out of the analyst’s predicted range.